Theriva Biologics (TOVX) Non Operating Income (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Non Operating Income of $83000.0 for Q1 2026, down 10.75% year-over-year from $93000.0 in Q1 2025, and up 23.88% quarter-over-quarter from $67000.0 in Q4 2025.
Theriva Biologics (TOVX) Non Operating Income (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Non Operating Income for 17 consecutive years, with $83000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 10.75% year-over-year to $83000.0; the TTM figure through Mar 2026 stood at $303000.0 (down 45.8% YoY), while the FY2025 annual figure was $312000.0, down 54.98% from the prior year.
- Non Operating Income advanced to $83000.0 in Q1 2026 per TOVX's latest filing, from $67000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $388000.0 in Q3 2023 and bottomed at -$21000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $176647.1 across 5 years, with a median of $161000.0 in 2022.
- Annual changes were most pronounced in 2022 — Non Operating Income surged 15600.0% — and 2025, when it sank 59.03%.
- Theriva Biologics' Non Operating Income stood at $314000.0 in 2022, then decreased by 1.91% to $308000.0 in 2023, then slumped by 56.82% to $133000.0 in 2024, then sank by 49.62% to $67000.0 in 2025, then grew by 23.88% to $83000.0 in 2026.
- Business Quant data shows TOVX's Non Operating Income at $83000.0 in Q1 2026, $67000.0 in Q4 2025, and $79000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78,000.00 |
| Mar 31, 2026 | 83,000.00 |
| Dec 31, 2025 | 67,000.00 |
| Sep 30, 2025 | 79,000.00 |
| Jun 30, 2025 | 74,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Dec 31, 2024 | 133,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Jun 30, 2024 | 172,000.00 |
| Mar 31, 2024 | 227,000.00 |
| Dec 31, 2023 | 308,000.00 |
| Sep 30, 2023 | 388,000.00 |
| Jun 30, 2023 | 377,000.00 |
| Mar 31, 2023 | 370,000.00 |
| Dec 31, 2022 | 314,000.00 |
| Sep 30, 2022 | 161,000.00 |
| Jun 30, 2022 | 17,000.00 |
| Mar 31, 2022 | -21,000.00 |
| Dec 31, 2021 | 2,000.00 |
| Sep 30, 2021 | 2,000.00 |